Bensch Clinical Research LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,233	60
2024	Research	$5,613	4
2023	Research	$32,831	8
2022	Research	$28,686	13
2021	Research	$71,433	15
2020	Research	$39,515	6
2019	Research	$26,329	7

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $47,733 80 payments
Roche Products Limited $46,761 9 payments
Sanofi US Services Inc. $34,680 7 payments
Amphastar Pharmaceuticals, Inc. $32,150 2 payments
Teva Pharmaceuticals USA, Inc. $26,048 10 payments
Genentech, Inc. $22,267 5 payments

Studies the money was for Research payments · program years 2019–2025

Open Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps $46,761 9 payments
Registry of Asthma Patients Initiating DUPIXENT (RAPID) $36,858 76 payments
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) $34,680 7 payments
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $26,048 10 payments
Phamacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $24,394 1 payment
PH Iib of Mstt1041a in Severe Uncontrolled Asthma $22,267 5 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis $10,875 4 payments
Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $7,756 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.